Physician profile
Julie Prieboy
NPI 1366743114
$10,930.17
in general payments reported to CMS, 2019-2025
69 companies · $4,354 in 2025
The $4,354 reported for 2025 was more than what 91% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,104 · 2022: $1,439 · 2023: $1,608 · 2024: $2,426 · 2025: $4,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,927 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,927.36 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,736.17 | 2023-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals Lp | $998.87 | 2021-2025 | Calquence, Lynparza, Enhertu |
| Janssen Biotech, INC. | $662.25 | 2021-2025 | Talvey, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $557.08 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $468.80 | 2022-2025 | |
| Abbvie INC. | $412.67 | 2023-2025 | |
| Daiichi Sankyo INC. | $378.69 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Amgen INC. | $370.45 | 2021-2023 | Lumakras |
| Astellas Pharma US INC | $363.53 | 2022-2025 | Padcev, Xtandi |
| Celgene Corporation | $339.62 | 2022-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $290.64 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $249.48 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Incyte Corporation | $241.82 | 2021-2025 | Jakafi |
| Gilead Sciences, INC. | $211.71 | 2021-2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $188.68 | 2021-2023 | Xarelto |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $174.23 | 2022-2025 | Polivy, Lunsumio, Venclexta |
| Jazz Pharmaceuticals INC. | $162.88 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $157.68 | 2021-2025 | Qinlock, Romvimza |
| Genzyme Corporation | $145.87 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $133.00 | 2021-2023 | Imbruvica |
| Eisai INC. | $122.76 | 2021-2025 | |
| Array Biopharma INC | $120.51 | 2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $117.21 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $112.12 | 2021-2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $111.78 | 2024-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $110.50 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $110.35 | 2021-2025 | |
| Seagen INC. | $107.19 | 2021-2023 | Padcev |
| Acrotech Biopharma INC. | $105.67 | 2022-2025 | Beleodaq |
| Stemline Therapeutics INC. | $98.41 | 2023-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $91.94 | 2024-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $75.94 | 2021-2025 | Libtayo |
| Tersera Therapeutics LLC | $75.66 | 2023-2025 | Quzyttir, Xermelo, Zoladex |
| Agios Pharmaceuticals, INC. | $73.01 | 2023-2025 | Pyrukynd |
| Morphosys, US INC. | $72.62 | 2021-2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $69.93 | 2024-2025 | Clonoseq |
| Caris Mpi, INC. | $67.72 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $65.77 | 2021-2024 | Brukinsa |
| Exelixis INC. | $62.11 | 2024-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $56.57 | 2021-2024 | |
| Mirati Therapeutics, INC. | $47.56 | 2023-2024 | Krazati |
| Iovance Biotherapeutics, INC. | $47.44 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $45.21 | 2021-2025 | Gavreto, Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $42.39 | 2023-2025 | Fotivda |
| Tolmar Pharmaceuticals, INC. | $39.05 | 2022 | |
| Pharmaessentia USA Corporation | $38.97 | 2023-2025 | Besremi |
| Pharming Healthcare, INC. | $38.88 | 2023-2024 | Ruconest |
| Myovant Sciences INC. | $36.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $34.73 | 2021-2023 | Givlaari |
| Acceleron Pharma, INC. | $34.42 | 2021 | |
| Syndax Pharmaceuticals, INC. | $34.18 | 2025 | |
| Puma Biotechnology, INC. | $32.12 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $31.93 | 2021-2022 | |
| Springworks Therapeutics, INC. | $31.41 | 2025 | |
| Coherus Oncology, INC. | $30.85 | 2025 | Loqtorzi |
| Tactile Systems Technology INC | $26.55 | 2025 | Nimbl, Flexitouch Plus |
| Stryker Corporation | $26.01 | 2025 | Optablate |
| Beone Medicines USA, INC. | $24.95 | 2025 | Tevimbra |
| Sobi, INC | $24.93 | 2025 | |
| Clovis Oncology, INC. | $22.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.85 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.97 | 2025 | Danziten |
| Celltrion USA INC. | $21.22 | 2025 | Vegzelma |
| Immunogen, INC. | $17.52 | 2023 | Elahere |
| Kite Pharma, INC. | $17.44 | 2023 | Yescarta |
| Recordati_rare_diseases_inc. | $17.00 | 2025 | Enjaymo |
| Emd Serono, INC. | $16.98 | 2024 | |
| Amag Pharmaceuticals, INC. | $16.70 | 2022 | |
| Geron Corporation | $15.91 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Prieboy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.